Think of it as radical bio-intelligence
We combine artificial intelligence with automation to conduct experimental biology at scale — testing thousands of compounds on hundreds of cellular disease models in parallel. Our embrace of systems biology and our commitment to an unbiased approach are leading to novel discoveries. With every experiment, our system gets smarter.
We’re using technology to accelerate every step in drug discovery.
In just a few years we’ve built the world’s largest dataset of biological images. Using the latest in artificial intelligence methods, we’re training our algorithms on this data to predict important properties of new medicines with the goal of discovering treatments for hundreds of diseases.
“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”
Recursion Scientific Advisor
Our investors
The latest news
Articles and Press Releases
01.07.19
Options Exercised by Takeda and AI Collaboration Extended
From collaboration to licensing options in less than 18 months
01.04.19
Recursion Signs Global Licensing Agreement
Contract signed with the Ohio State Innovation Foundation to Develop REC-2282 to Treat Neurofibromatosis Type 2
11.08.18
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Recursion Secures $1.6M NIH Phase 2 SBIR Grant for Senescence
